GLP-1 and GIP: The Two Incretins
Incretin Biology
50-70% of insulin
Incretins account for 50-70% of the insulin released after eating. These two gut hormones, GLP-1 and GIP, are the reason oral glucose triggers far more insulin than the same dose injected into a vein.
Nauck et al., Diabetes Obes Metab, 2021
Nauck et al., Diabetes Obes Metab, 2021
View as imageSwallow a glucose drink and your pancreas releases two to three times more insulin than if the same amount of glucose were delivered directly into your bloodstream. This phenomenon, called the incretin effect, was first demonstrated in the 1960s and accounts for 50-70% of the total insulin response after a meal.[1] Two gut hormones are responsible: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). They are secreted within minutes of eating, amplify insulin release in a glucose-dependent manner, and are destroyed within two minutes by the enzyme dipeptidyl peptidase-4 (DPP-4).
The incretin concept has a history stretching back more than a century, beginning with early observations that gut extracts could lower blood glucose.[2] That long, winding path has produced some of the most effective diabetes and obesity drugs ever developed. This article maps the biology of both hormones: where they come from, what they do, how they differ, and why the combination of GIP and GLP-1 receptor activation has proven more powerful than either alone. Each major section connects to a dedicated cluster article for deeper exploration.
Key Takeaways
- GIP and GLP-1 together account for 50-70% of the insulin secreted after oral glucose intake, a phenomenon called the incretin effect (Nauck et al., 2021)
- Both hormones work through G-protein coupled receptors that increase intracellular cAMP in pancreatic beta-cells, stimulating insulin secretion only when glucose is elevated (Seino et al., 2010)
- GIP is the quantitatively larger incretin, responsible for most of the insulin-amplifying effect in healthy individuals, while GLP-1 contributes primarily through glucagon suppression and gastric emptying delay (Baggio and Drucker, 2007)
- In type 2 diabetes, GIP loses most of its insulinotropic effect while GLP-1's action remains largely intact, which is why early drug development focused on GLP-1 alone (Nauck et al., 2021)
- Tirzepatide, the first dual GIP/GLP-1 receptor agonist, produced 20.9% body weight reduction in the SURMOUNT-1 trial and outperformed semaglutide (a GLP-1-only agonist) for both HbA1c and weight loss in the SURPASS-2 trial (Jastreboff et al., 2022; Frias et al., 2021)
- Both hormones have actions far beyond insulin: GIP promotes fat storage and bone formation, GLP-1 slows gastric emptying and reduces appetite, and both show neuroprotective effects in preclinical research (Drucker and Holst, 2023)
What Are Incretins?
Incretins are gut hormones released after eating that amplify insulin secretion above what glucose alone would trigger. The term itself was coined in the early twentieth century, though the concept's roots go deeper. Rehfeld (2018) traces the incretin idea back to 1902, when British physiologists Bayliss and Starling discovered secretin, the first identified hormone, in gut extracts that stimulated pancreatic secretion.[2] By the 1930s, researchers had shown that intestinal extracts could lower blood glucose, suggesting the gut produced substances that acted on the endocrine pancreas.
The decisive experiment came decades later. In the 1960s, researchers compared insulin responses to glucose given orally versus intravenously at identical blood glucose concentrations. Oral glucose consistently produced a larger insulin response. This gap, the incretin effect, proved that something released from the gut during digestion was amplifying the pancreatic response. Nauck et al. (2021) established the current consensus that this effect accounts for approximately 50-70% of the total postprandial insulin secretion in healthy individuals.[1] For a dedicated exploration of how this was discovered and measured, see our article on the incretin effect.
Two hormones produce this effect: GIP and GLP-1. They are additive, meaning their combined insulinotropic effect is greater than either alone. Rehfeld (2018) argues that the incretin concept may now be too narrow, because other gut hormones such as cholecystokinin (CCK) and peptide YY likely contribute to insulin modulation during complex meals containing protein, fat, and carbohydrates rather than pure glucose.[2]
GIP: The Quantitatively Dominant Incretin
Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino-acid peptide secreted by K-cells in the duodenum and jejunum (the upper small intestine). It was originally called "gastric inhibitory polypeptide" because it was discovered through its ability to inhibit gastric acid secretion, but its primary physiological role turned out to be insulin stimulation. The name was reinterpreted rather than replaced.
GIP is released within minutes of nutrient ingestion, with plasma levels reaching 50-100 picomolar within 30 minutes of a glucose load in healthy individuals.[3] Carbohydrates and fats are the primary secretagogues. GIP acts by binding to the GIP receptor (GIPR), a G-protein coupled receptor on pancreatic beta-cells, which activates adenylyl cyclase and raises intracellular cyclic AMP (cAMP). This cAMP increase amplifies glucose-stimulated insulin secretion but cannot trigger insulin release on its own when glucose is low, a safety mechanism that prevents hypoglycemia.
Baggio and Drucker (2007) established that GIP is quantitatively the more important incretin in healthy individuals, responsible for the majority of the meal-stimulated insulin amplification.[4] GIP also enhances postprandial glucagon secretion from alpha-cells, a seemingly counterintuitive action. In the postprandial state, this glucagon response may serve to prevent excessive insulin-mediated hypoglycemia and to direct nutrient disposal toward liver glycogen synthesis.
Beyond the pancreas, GIP has distinct actions on adipose tissue and bone. GIP facilitates fat deposition by promoting triglyceride storage in white adipose tissue through direct effects on adipocytes that are independent of its insulin-stimulating activity.[1] On bone, GIP stimulates osteoblast proliferation and inhibits osteoblast apoptosis, promoting bone formation. Seino et al. (2010) showed that GIP also inhibits bone resorption, giving it a dual protective role in skeletal maintenance.[3]
For a closer look at the cells that produce GIP, see our article on L-cells and K-cells: where your gut makes incretin hormones.
GLP-1: The Multifunctional Incretin
Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid peptide (in its active 7-36 amide form) secreted by L-cells in the ileum and colon (the lower intestine). Despite being produced further downstream in the gut, GLP-1 appears in the bloodstream within minutes of eating, suggesting neural or paracrine mechanisms trigger early secretion before nutrients physically reach the L-cells.
GLP-1 acts through its own receptor (GLP-1R), another G-protein coupled receptor that raises cAMP in beta-cells, stimulating glucose-dependent insulin secretion through the same general mechanism as GIP. The effects are additive: when both GIP and GLP-1 are present, the insulin response is greater than with either hormone alone.[3]
Where GLP-1 differs from GIP is in its non-insulinotropic actions. Baggio and Drucker (2007) catalogued several that make GLP-1 a more versatile metabolic regulator:[4]
Glucagon suppression. GLP-1 inhibits glucagon secretion from alpha-cells in a glucose-dependent manner. This contrasts with GIP, which enhances glucagon release. The net effect of GLP-1 activity is reduced hepatic glucose output.
Gastric emptying delay. GLP-1 slows the rate at which food leaves the stomach, spreading nutrient absorption over a longer period and reducing postprandial glucose spikes. This effect has clinical significance: the delayed gastric emptying associated with GLP-1 receptor agonists is one reason these drugs carry warnings about retained gastric contents before anesthesia.
Appetite suppression and satiety. Sustained GLP-1 receptor activation reduces food intake and promotes weight loss. The GLP-1 receptor is expressed in hypothalamic and brainstem regions that regulate appetite, and GLP-1 agonists produce measurable changes in reward-related brain activity. For a deeper look at this pathway, see our article on the gut-brain axis of blood sugar.
Beta-cell preservation. In preclinical models, both GIP and GLP-1 promote beta-cell proliferation and inhibit beta-cell apoptosis, expanding functional beta-cell mass. Whether this translates to meaningful beta-cell preservation in humans with type 2 diabetes remains an open question.
The DPP-4 Problem: Why Native Incretins Are So Short-Lived
Both GIP and GLP-1 are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), which cleaves two amino acids from the N-terminus of each peptide. The half-life of intact GIP is approximately 5-7 minutes; for GLP-1, it is closer to 2 minutes.[4] This rapid degradation means that only a fraction of secreted incretin reaches its target receptors in active form. In fact, GLP-1 concentrations in the hepatic portal vein (the blood vessel carrying gut hormones to the liver) may be several-fold higher than what is measured in peripheral blood, because DPP-4 in the vascular endothelium destroys most of it before it reaches the general circulation.
This short half-life is not a design flaw. It allows tight temporal control: incretins amplify insulin secretion during and immediately after meals, then disappear so that insulin secretion returns to baseline. The problem arises when you want to harness incretin effects therapeutically. Native GLP-1 or GIP would need to be infused continuously to maintain active levels.
Two pharmaceutical strategies have emerged. DPP-4 inhibitors (sitagliptin, saxagliptin, and others) block the enzyme, prolonging the action of endogenous GIP and GLP-1. This raises active incretin levels by two- to three-fold. GLP-1 receptor agonists (semaglutide, liraglutide, exenatide, and others) are modified GLP-1 molecules that resist DPP-4 cleavage, achieving pharmacological GLP-1 receptor activation that is orders of magnitude stronger than the endogenous signal.[5] For a detailed exploration of this enzyme, see our article on how DPP-4 destroys incretins.
When Incretins Fail: The Type 2 Diabetes Problem
One of the most clinically significant discoveries in incretin biology is that the incretin effect is severely diminished in people with type 2 diabetes. In healthy individuals, oral glucose produces approximately 50-70% more insulin than the same glycemic stimulus given intravenously. In people with type 2 diabetes, this amplification is reduced to roughly 20% or less.[1]
The secretion of GIP and GLP-1 from gut cells is largely preserved in type 2 diabetes. The defect lies downstream. Nauck et al. (2021) described the critical asymmetry: GIP has lost most of its acute insulinotropic activity in type 2 diabetes, for largely unknown reasons, while the insulinotropic effects of GLP-1 remain only slightly impaired.[1] This observation shaped early drug development. Because GIP appeared ineffective in the very patients who needed treatment, pharmaceutical efforts focused on GLP-1, the incretin that still worked.
The reasons for GIP resistance in type 2 diabetes remain incompletely understood. Possible mechanisms include downregulation of GIP receptors on beta-cells, impaired intracellular signaling downstream of the receptor, and generalized beta-cell dysfunction that blunts the response to any secretagogue. Seino et al. (2010) noted that GIP's insulinotropic effects were "severely reduced" but not abolished, suggesting partial receptor responsiveness that might be restored under certain conditions.[3]
This picture was complicated by the discovery that pharmacological GIP receptor activation, especially in combination with GLP-1 receptor activation, produces effects in type 2 diabetes that native GIP alone cannot. The success of tirzepatide (discussed below) forced a reassessment of whether GIP's failure in type 2 diabetes is absolute or context-dependent.
Beyond Glucose: The Expanding Incretin Landscape
Drucker and Holst (2023) surveyed the evidence for incretin actions beyond glycemic control and identified multiple extrapancreatic pathways with clinical relevance.[5]
Cardiovascular system. The SELECT trial (Lincoff et al., 2023), enrolling 17,604 patients with overweight or obesity and preexisting cardiovascular disease but without diabetes, demonstrated that semaglutide 2.4 mg weekly reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72-0.90, P<0.001) over a mean follow-up of 39.8 months.[6] Whether these cardiovascular benefits stem from weight loss, direct vascular effects of GLP-1R activation, anti-inflammatory mechanisms, or a combination remains an active area of investigation.
Central nervous system. Both GIP and GLP-1 receptors are expressed in the brain. Preclinical data suggest neuroprotective effects in models of Alzheimer's and Parkinson's disease, with clinical trials underway. The appetite-suppressing effects of GLP-1 are centrally mediated, predominantly through receptors in the hypothalamus and brainstem. Whether GIP contributes to central appetite regulation in humans remains uncertain; animal studies suggest it does, but human data have been contradictory.[1]
Bone and adipose tissue. GIP promotes bone formation through osteoblast stimulation and inhibits bone resorption. GLP-1 has weaker direct bone effects but inhibits bone resorption through an indirect pathway. In adipose tissue, GIP promotes triglyceride storage, while GLP-1 does not have this lipogenic action. This difference in fat metabolism effects is one reason the combination of GIP and GLP-1 agonism produces different metabolic outcomes than GLP-1 agonism alone.
Liver. GLP-1 receptor agonists reduce hepatic steatosis (fatty liver) in clinical trials, with ongoing studies investigating effects on metabolic dysfunction-associated steatotic liver disease (MASLD). Drucker (2024) noted that investigators are now interrogating GLP-1-based therapies for metabolic liver disease, peripheral artery disease, and neurodegenerative conditions.[7]
The Therapeutic Revolution: From GLP-1 Agonists to Dual Agonists
GLP-1 Receptor Agonists
The first generation of incretin-based drugs targeted GLP-1 alone. Exenatide, approved in 2005, was the first GLP-1 receptor agonist. It was followed by liraglutide (2010), dulaglutide (2014), and semaglutide (2017 for diabetes, 2021 for obesity).
Semaglutide set new benchmarks. In the STEP 1 trial (Wilding et al., 2021), 1,961 adults with obesity but without diabetes were randomized to semaglutide 2.4 mg weekly or placebo for 68 weeks. The semaglutide group lost an average of 14.9% of body weight, compared to 2.4% with placebo, a treatment difference of 12.4 percentage points (P<0.001). Half of the semaglutide group (50.5%) achieved weight loss of 15% or greater, versus 4.9% on placebo.[8]
Dual GIP/GLP-1 Receptor Agonists
The resurgence of interest in GIP came with the development of tirzepatide, a synthetic peptide that activates both the GIP and GLP-1 receptors. This was a conceptual departure: if GIP was broken in type 2 diabetes, why combine it with GLP-1?
The SURPASS-2 trial (Frias et al., 2021) provided the first head-to-head answer. In 1,879 patients with type 2 diabetes, tirzepatide at all three doses (5, 10, and 15 mg) was statistically superior to semaglutide 1 mg for HbA1c reduction. The highest tirzepatide dose reduced HbA1c by 2.30 percentage points versus 1.86 for semaglutide. Weight loss was also significantly greater: the 15 mg dose produced 5.5 kg more weight loss than semaglutide (P<0.001).[9] A limitation: semaglutide was tested at 1 mg, not the higher 2.4 mg dose used for obesity.
The SURMOUNT-1 trial (Jastreboff et al., 2022) tested tirzepatide specifically for obesity. In 2,539 adults with a BMI of 30 or greater (or 27 or greater with complications), the 15 mg dose produced a mean weight reduction of 20.9% over 72 weeks, compared to 3.1% with placebo. The 10 mg and 15 mg groups saw 50% and 57% of participants, respectively, achieve 20% or greater weight loss (versus 3% on placebo).[10]
These results raised a fundamental question: why does combined GIP/GLP-1 receptor activation work better than GLP-1 alone, given that GIP is supposedly impaired in metabolic disease? For a side-by-side comparison of clinical outcomes, see our article on tirzepatide vs semaglutide. Several hypotheses are being investigated. Pharmacological GIP receptor activation at supraphysiological levels may overcome the resistance seen with endogenous GIP. The two receptors may produce synergistic intracellular signaling when activated simultaneously. And GIP's effects on adipose tissue, bone, and potentially the brain may complement GLP-1's glucoregulatory and appetite-suppressing effects in ways that are only beginning to be characterized.
Triple Agonists: The Next Generation
The logic of combining receptor activations has extended to triple agonists. Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously, adding glucagon's lipolytic and thermogenic effects to the dual incretin agonism. Phase 2 data showed weight reductions approaching 24% at the highest dose over 48 weeks, surpassing the results seen with tirzepatide. Phase 3 trials are underway.
Drucker (2024) described the current landscape as one of rapid differentiation: GIP-GLP-1 receptor co-agonists, GIP-blocking/GLP-1-activating approaches (such as maritide), and GLP-1/glucagon receptor co-agonists (such as survodutide) are all in clinical development.[7] The diversity of approaches reflects genuine uncertainty about which receptor combination will prove optimal for which patient population.
Open Questions and Limitations
The incretin field has moved faster than the mechanistic understanding can follow. Several critical questions remain unresolved.
Why does pharmacological GIP agonism work in type 2 diabetes when endogenous GIP does not? The most common explanation, that pharmacological doses overcome receptor downregulation, remains untested in humans. Alternative hypotheses involving receptor desensitization, differential signaling bias, or synergistic receptor cross-talk have not been conclusively distinguished.
What is GIP's role in human appetite regulation? Nauck et al. (2021) noted that while animal studies suggest GIP reduces food intake, human studies "do not confirm these findings."[1] Tirzepatide clearly produces greater appetite suppression than GLP-1 agonism alone, but whether this is driven by GIP receptor activation in the brain, GIP's effects on adipose tissue signaling, or synergistic GIP/GLP-1 receptor interactions remains unclear.
Are the cardiovascular benefits of GLP-1 agonists direct or indirect? The SELECT trial demonstrated cardiovascular benefit, but the mechanism is debated. Weight loss alone improves cardiovascular risk factors. GLP-1 receptors in blood vessels and the heart suggest direct protective effects. Anti-inflammatory properties may contribute. Separating these effects in humans is extremely difficult.
What are the long-term consequences of sustained incretin receptor activation? The longest trials run 3-4 years. Beta-cell mass changes, bone density effects, and cancer risk with decades of use remain unknown. Drucker (2024) specifically flagged bone density, fractures, muscle strength, and pancreatic disorders as areas requiring continued safety monitoring.[7]
Does the incretin concept need expansion? Rehfeld (2018) argued that limiting incretins to GIP and GLP-1 may be too narrow, because normal mixed meals (containing protein, fat, and complex carbohydrates) trigger additional gut hormones that contribute to the insulin response.[2] Whether CCK, secretin, or other peptides qualify as "incretins" depends on whether they meet the strict definition of augmenting glucose-dependent insulin secretion at physiological concentrations.
The Bottom Line
GLP-1 and GIP are gut hormones that amplify insulin secretion after eating, together accounting for 50-70% of the postprandial insulin response. Despite sharing a common receptor-signaling mechanism, they diverge in critical ways: GIP promotes fat storage and bone formation while GLP-1 suppresses glucagon, slows gastric emptying, and reduces appetite. The impairment of GIP signaling in type 2 diabetes initially sidelined GIP as a therapeutic target, but the success of dual GIP/GLP-1 agonists like tirzepatide, which outperform GLP-1-only drugs for both glycemic control and weight loss, has forced a fundamental reassessment of incretin pharmacology. The field is now rapidly expanding into triple agonists and novel combinations, with clinical applications extending beyond diabetes and obesity to cardiovascular disease, liver disease, and neurodegeneration.